Therapeutic Asset Ratings

130 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Fruquintinib Head and Neck Squamous Cell Carcinoma	Immunitas Therapeutics	P1/2	CC (41)
Idp-001 Head and Neck Squamous Cell Carcinoma	InduPro, Inc.	P1/2	CC (41)
immunoglobulin G1-kappa, anti-[Homo sapiens KLRB1 (killer cell lectin like receptor B1, NKR-P1A, natural killer cell surface protein P1A, CLEC5B, CD161)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-2301 (96.9%) -(IGHD) -IGHJ401 (85.7%), Q120>R (113), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG101, G1m17,1 CH1 K120, CH3 D12, L14, G1v29 CH2 A84.4 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 G1v29 CH2 N84.4>A (301) (235-344), CH3 D12 (360), L14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 (94.7%) -IGKJ401 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, non-glycosylated Head and Neck Squamous Cell Carcinoma	Immunitas Therapeutics	P1/2	CC (41)
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific Head and Neck Squamous Cell Carcinoma	Merus B.V.	P1/2	CC (41)
ipn01194 Head and Neck Squamous Cell Carcinoma	Ipsen	P1/2	CC (41)
MONOCLONAL ANTIBODY NEO-201 Head and Neck Squamous Cell Carcinoma	Precision Biologics, Inc	P1/2	CC (41)
neo212 Head and Neck Squamous Cell Carcinoma	Neonc Technologies, Inc.	P1/2	CC (41)
Osimertinib Head and Neck Squamous Cell Carcinoma	Merus B.V.	P1/2	CC (41)
PEXMETINIB Head and Neck Squamous Cell Carcinoma	Dan Zandberg	P1/2	CC (41)
Rilvegostomig Head and Neck Squamous Cell Carcinoma	AstraZeneca	P1/2	CC (41)
Rtx-224 Head and Neck Squamous Cell Carcinoma	Rubius Therapeutics	P1/2	CC (41)
Sacituzumab Tirumotecan Head and Neck Squamous Cell Carcinoma	Klus Pharma Inc.	P1/2	CC (41)
SX682 Head and Neck Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CC (41)
Ter-2013 Head and Neck Squamous Cell Carcinoma	Terremoto Biosciences Inc.	P1/2	CC (41)
tt-10 Head and Neck Squamous Cell Carcinoma	Portage Biotech	P1/2	CC (41)
tt-4 Head and Neck Squamous Cell Carcinoma	Portage Biotech	P1/2	CC (41)
tu2218 Head and Neck Squamous Cell Carcinoma	TiumBio Co., Ltd.	P1/2	CC (41)
Valemetostat Head and Neck Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CC (41)
Vls-1488 Head and Neck Squamous Cell Carcinoma	Volastra Therapeutics, Inc.	P1/2	CC (41)
Vofatamab Head and Neck Squamous Cell Carcinoma	Fusion Pharmaceuticals Inc.	P1/2	CC (41)
Zovostotug Head and Neck Squamous Cell Carcinoma	OncoResponse, Inc.	P1/2	CC (41)
prt3645 Head and Neck Squamous Cell Carcinoma	Prelude Therapeutics	P1	CC (40)
Xmab808 Head and Neck Squamous Cell Carcinoma	Xencor, Inc.	P1	CC (40)
[111in]-fpi-2107 Head and Neck Squamous Cell Carcinoma	AstraZeneca	P1	C (37)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)- Head and Neck Squamous Cell Carcinoma	Nurix Therapeutics, Inc.	P1	C (37)

Showing 51 to 75 of 130 assets

PreviousPage 3 of 6Next